DMKJ
David M. Knott Jr Portfolio holdings
AUM
$221M
This Quarter Return
+12.82%
1 Year Return
+22.52%
3 Year Return
+148.91%
5 Year Return
–
10 Year Return
–
AUM
$221M
AUM Growth
+$221M
(+4.1%)
Cap. Flow
-$7.42M
Cap. Flow
% of AUM
-3.36%
Top 10 Holdings %
Top 10 Hldgs %
71.57%
Holding
93
New
9
Increased
15
Reduced
13
Closed
8
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$3.45M |
| 2 |
LENZ
LENZ Therapeutics
LENZ
|
$2.4M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$2.11M |
| 4 |
Alkermes
ALKS
|
$1.4M |
| 5 |
Liquidia Corp
LQDA
|
$1.12M |
Top Sells
| 1 |
Pfizer
PFE
|
$4.36M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$3.12M |
| 3 |
Janus Henderson AAA CLO ETF
JAAA
|
$2.87M |
| 4 |
Ardelyx
ARDX
|
$2.42M |
| 5 |
OmniAb
OABI
|
$2.36M |
Sector Composition
| 1 | Healthcare | 31.49% |
| 2 | Materials | 24.07% |
| 3 | Financials | 19.36% |
| 4 | Communication Services | 9.05% |
| 5 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Alkermes
ALKS
$4.95B
| $1.4M | 0.64% |
+49,000
| New | +$1.4M |
|
27
Viridian Therapeutics
VRDN
$1.59B
| $1.28M | 0.58% |
91,483
+61,483
| +205% | +$860K |
|
28
Panagram BBB-B CLO ETF
CLOZ
$841M
| $1.28M | 0.58% |
47,807
| – | – |
|
29
Bristol-Myers Squibb
BMY
$96.7B
| $1.25M | 0.57% |
27,000
+8,000
| +42% | +$370K |
|
30
Ryman Hospitality Properties
RHP
$6.29B
| $1.18M | 0.54% |
12,000
| – | – |
|
|
31
Liquidia Corp
LQDA
$2.52B
| $1.12M | 0.51% |
+90,000
| New | +$1.12M |
|
32
Johnson & Johnson
JNJ
$429B
| $1.06M | 0.48% |
6,922
+6,000
| +651% | +$917K |
|
33
Myriad Genetics
MYGN
$633M
| $956K | 0.43% |
180,000
+20,000
| +13% | +$106K |
|
34
AbbVie
ABBV
$374B
| $935K | 0.42% |
5,037
| – | – |
|
|
MREO
35
Mereo BioPharma
MREO
$275M
| $865K | 0.39% |
319,337
| – | – |
|
36
Corteva
CTVA
$49.2B
| $824K | 0.37% |
11,051
| – | – |
|
37
Microsoft
MSFT
$3.76T
| $796K | 0.36% |
1,600
| – | – |
|
38
Solid Biosciences
SLDB
$448M
| $791K | 0.36% |
162,440
+30,440
| +23% | +$148K |
|
39
Kimberly-Clark
KMB
$42.5B
| $774K | 0.35% |
6,000
| – | – |
|
40
Collegium Pharmaceutical
COLL
$1.25B
| $695K | 0.32% |
23,511
-14,962
| -39% | -$442K |
|
41
DuPont de Nemours
DD
$31.6B
| $646K | 0.29% |
9,418
| – | – |
|
42
IBM
IBM
$227B
| $631K | 0.29% |
2,142
| – | – |
|
43
Axsome Therapeutics
AXSM
$6.09B
| $626K | 0.28% |
+6,000
| New | +$626K |
|
|
AUTL
44
Autolus Therapeutics
AUTL
$383M
| $616K | 0.28% |
270,000
-150,000
| -36% | -$342K |
|
45
Mondelez International
MDLZ
$79.3B
| $607K | 0.28% |
9,000
| – | – |
|
46
Madrigal Pharmaceuticals
MDGL
$9.7B
| $605K | 0.27% |
+2,000
| New | +$605K |
|
47
Arcus Biosciences
RCUS
$1.24B
| $570K | 0.26% |
70,000
+58,000
| +483% | +$472K |
|
|
CYBN
48
Cybin
CYBN
$142M
| $561K | 0.25% |
66,880
| – | – |
|
49
Canadian Natural Resources
CNQ
$65B
| $528K | 0.24% |
16,800
| – | – |
|
50
Apple
AAPL
$3.54T
| $512K | 0.23% |
2,494
| – | – |
|